| 3.29 0.23 (7.52%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.9 | 1-year : | 4.56 |
| Resists | First : | 3.34 | Second : | 3.9 |
| Pivot price | 2.82 |
|||
| Supports | First : | 2.7 | Second : | 2.31 |
| MAs | MA(5) : | 3 |
MA(20) : | 2.89 |
| MA(100) : | 3.67 |
MA(250) : | 5.32  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 90.8 |
D(3) : | 76.1 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 10.13 | Low : | 2.31 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FULC ] has closed Bollinger Bands are 11.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.31 - 3.32 | 3.32 - 3.33 |
| Low: | 3.02 - 3.03 | 3.03 - 3.05 |
| Close: | 3.27 - 3.29 | 3.29 - 3.31 |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fri, 11 Apr 2025
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Fri, 11 Apr 2025
Fulcrum Expands Team with New Hires, Grants $263K Worth of Stock Options - Stock Titan
Tue, 08 Apr 2025
We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance
Fri, 04 Apr 2025
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry - simplywall.st
Tue, 01 Apr 2025
Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com
Wed, 05 Mar 2025
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 97.1 (%) |
| Shares Short | 5,220 (K) |
| Shares Short P.Month | 4,440 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.5 |
| Profit Margin | -12.2 % |
| Operating Margin | -24.8 % |
| Return on Assets (ttm) | -4.8 % |
| Return on Equity (ttm) | -4.1 % |
| Qtrly Rev. Growth | -100 % |
| Gross Profit (p.s.) | 0.3 |
| Sales Per Share | 1.48 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -20.57 |
| PEG Ratio | 0 |
| Price to Book value | 0.73 |
| Price to Sales | 2.21 |
| Price to Cash Flow | -80 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|